Kedrion was among the companies that actively participated in “Italian Pharma: A Story of Innovation and Excellence,” an event hosted yesterday by the Consulate General of Italy in New York as part of the celebrations for Made in Italy Day. Bracco and Menarini were also key participants in this meeting, a talk spotlighting the strategic role of the Italian pharmaceutical industry as a key driver of economic growth and innovation, hosted by Fabrizio Di Michele, Consul General of Italy in New York.
Moderated by Mario Calvo-Platero, columnist for La Repubblica and “Direttore responsabile” of the New York Times Italia, the panel featured Paolo Marcucci, Chairman of Kedrion; Marco Campione, President and CEO of Blue Earth Diagnostics, a Bracco company; and Kenneth Hoberman, Chief Operating Officer and Co-Founder of Stemline Therapeutics. The panelists shared their companies’ extensive experiences in the US, where they maintain a robust and diversified presence across production, distribution, and research and development.
“I have been pleased to present in New York an initiative that highlights a strategic sector of excellence for our economy and for bilateral relations with the United States, which is perhaps less celebrated than the traditional symbols of our style, but no less fundamental: the Italian pharmaceutical industry,” stated Fabrizio Di Michele, Consul General of Italy in New York. “Today we celebrate the globally recognized capacity for innovation and quality of our companies, as demonstrated by their significant investments right here, in the Tristate area and throughout the United States.”
“This event was an opportunity for industry leaders to discuss the sector’s future, focusing on innovation and competitiveness to improve patient access to treatments,” stated Paolo Marcucci, Chairman of Kedrion. “Kedrion is dedicated to advancing research and development of new therapies to provide solutions for people with rare and serious diseases, with the ultimate goal of expanding global access to plasma-derived therapies for these patients. The United States represents a key strategic market and a vital hub for scientific innovation, crucial for our growth.”
Kedrion has been present in the United States since 2004, when it acquired its first plasma collection center in the country. In 2011, the company acquired the production plant in Melville, New York, a facility that today plays a key strategic role within the company’s global production network. The United States is Kedrion’s primary market, accounting for nearly 60% of the company’s total revenue.
The main plasma-derived products manufactured by Kedrion are approved in the United States. These include Albumin, Immunoglobulins, Coagulation Factors, Anti-Rabies Immunoglobulins, and Anti-D Immunoglobulins. Through our subsidiary KEDPLASMA, established in 2012, we manage almost 70 plasma collection centers across the United States. Out of a total of 5,200 employees, Kedrion employs 2,500 people in the US, distributed across KEDPLASMA centers, our Melville production plant, and our offices in Fort Lee.
The event was an opportunity to restate the company’s mission to meet the needs of an increasing number of patients worldwide by leveraging our expertise in plasma to expand our global reach. Our commitment to educating and increasing awareness about rare diseases, and to advocating for supportive policies in the biopharma sector continues to be steadfast.